[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,048,141
  • Shares Outstanding, K 47,598
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,970 K
  • EBIT $ -99 M
  • EBITDA $ -99 M
  • 60-Month Beta 0.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.52

Options Overview Details

View History
  • Implied Volatility 101.54% (+1.77%)
  • Historical Volatility 94.80%
  • IV Percentile 20%
  • IV Rank 10.31%
  • IV High 309.05% on 07/18/25
  • IV Low 77.70% on 10/24/25
  • Expected Move (DTE 28) 2.13 (4.94%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 93
  • Volume Avg (30-Day) 301
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 7,654
  • Open Int (30-Day) 5,208
  • Expected Range 40.91 to 45.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 4
  • High Estimate $-0.60
  • Low Estimate $-0.79
  • Prior Year $-0.58
  • Growth Rate Est. (year over year) -13.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.00 +53.68%
on 06/08/26
43.49 -1.06%
on 06/18/26
+12.05 (+38.90%)
since 05/18/26
3-Month
26.14 +64.61%
on 03/30/26
45.85 -6.15%
on 05/11/26
+14.33 (+49.93%)
since 03/18/26
52-Week
9.43 +356.31%
on 06/20/25
45.85 -6.15%
on 05/11/26
+32.75 (+318.58%)
since 06/18/25

Most Recent Stories

More News
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Availâ„¢ trial Results consistent with restoration of systemic PTH activity through serum calcium...

MBX : 43.03 (+3.46%)
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 43.03 (+3.46%)
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 43.03 (+3.46%)
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development...

MBX : 43.03 (+3.46%)
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated,...

MBX : 43.03 (+3.46%)
MBX Biosciences: Can Platform Validation Wait Until Late 2026 Without a Differentiation Problem?

Barchart Research What to Expect from MBX Earnings MBX Generated May 8, 2026 Current Price $40.97 EPS Estimate $$-0.68 Consensus Rating Strong Buy Average Move 4.47% MBX Biosciences: Can Platform Validation...

MBX : 43.03 (+3.46%)
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment...

MBX : 43.03 (+3.46%)
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 43.03 (+3.46%)
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 43.03 (+3.46%)
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 43.03 (+3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX...

See More

Key Turning Points

3rd Resistance Point 46.82
2nd Resistance Point 45.15
1st Resistance Point 44.09
Last Price 43.03
1st Support Level 41.37
2nd Support Level 39.70
3rd Support Level 38.64

See More

52-Week High 45.85
Last Price 43.03
Fibonacci 61.8% 31.94
Fibonacci 50% 27.64
Fibonacci 38.2% 23.34
52-Week Low 9.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.